Senior Scientist Biologics - Early Drug Candidates (100%)

GlycoEra AG

  • Wädenswil, Zurich
  • CDI
  • Temps-plein
  • Il y a 23 heures
Join a motivated cross‑functional team to drive early‑stage biologic drug candidates from design through process development and characterization, powered by hands‑on laboratory experimentation to build and elevate our pipeline portfolioAufgaben
  • Design, express, purify and optimize novel (glyco)proteins for early drug candidates, apply novel and state-of-the-art approaches and lab experiments
  • Scale expression from shake flasks to fed‑batch bioreactors; harvest, purify and prepare material
  • Analyze critical quality attributes using methods such as SDS‑PAGE, ELISA, HPLC, LC‑MS, SEC, CE and SPR
  • Maintain meticulous experimental records; prepare technical reports and presentations
  • Ensure compliance with SOPs, GMP, regulatory and quality standards
Qualifikation
  • Ph.D. in Biochemistry, Molecular Biology, Biotechnology or related field
  • Minimum of 4 years industrial Biologics experience in protein biochemistry and bioprocess development
  • Proven experience in engineering, expressing and purifying glycoproteins, mAbs or scaffolds
  • Hands‑on experience with upstream/downstream scale‑up and bioreactor operations
  • Sound experience with fast protein liquid chromatography using standard equipment like Äkta and different chromatography techniques
  • Proficiency in analytical protein characterization / CQAs
  • Solid background in genetic engineering, clone selection and cell line development
  • Experience using in silico/AI‑driven protein engineering and developability tools is a plus
  • Familiarity with GMP regulations and quality systems
  • Proactive problem‑solver who can multitask in fast‑paced environments
  • Excellent written and spoken English communication
If this role matches your profile, please upload your CV and motivation letter.GlycoEra AGGlycoEra AG is a biotech in Wädenswil, Switzerland, developing glycoengineered biologics using a proprietary platform technology for next‑generation therapeutics across multiple indications. Following our Series B financing, we are advancing GE8820—our precision IgG4‑targeted degrader—into first‑in‑human trials while expanding our pipeline of novel precision immunology therapies.

GlycoEra AG